Author Archives: Mark Senak

FDA Announces New Study on Endorsements and DTC Television Ads

In today’s Federal Register, the agency has announced that the Office of Prescription Drug Promotion (OPDP) is adding a new study effort to its research portfolio. The category of that body of research that is currently underway includes a range … Continue reading

Posted in DTC Advertising, FDA Policy | Tagged , , | Comments Off on FDA Announces New Study on Endorsements and DTC Television Ads

Thumbs Up, Thumbs Down – Minimizing Votes in AdComms

The FDA Commissioner has said he would like to limit votes in AdComms – is that really a good idea? Continue reading

Posted in Advisory Committee Prepapartion, FDA Policy | Tagged , , | Comments Off on Thumbs Up, Thumbs Down – Minimizing Votes in AdComms

Big Decisions – Reviewing FDA Advisory Committee Outcomes Since 2020

In January we took a look at FDA Advisory Committees (AdComms) – FDA AdComms – When the Going Gets Tough – noting, among other things that there had not only been fewer meetings but also that it appeared that the … Continue reading

Posted in Advisory Committee Prepapartion | Tagged , , , , | Comments Off on Big Decisions – Reviewing FDA Advisory Committee Outcomes Since 2020

Emerging from Emergency – Two COVID-Related Developments This Week

Two announcements occurred this week, both of note and connected only by the fact that they are emblematic of the slow metamorphosis from a COVID emergency world to a post-COVID emergency one. Emergency Ends – First, the Biden Administration announced … Continue reading

Posted in FDA Image, FDA Policy | Tagged , , , , | Comments Off on Emerging from Emergency – Two COVID-Related Developments This Week

What They Said – Looking Back at FDA Press Releases During 2022

Each year Eye on FDA provides a look-back to see what the agency was talking about and what has changed over time. This year is a telling one and FDA may be changing the nature of the way they are … Continue reading

Posted in FDA Image | Tagged , | Comments Off on What They Said – Looking Back at FDA Press Releases During 2022